https://www.researchgate.net/publication/329336851_Thiazolidinediones_and_their_drug_interactions_involving_CYP_enzymes
https://www.ejmanager.com/mnstemps/61/61-1539504628.pdf?t=1543816308
·
Thiazolidinediones
(TZDs) include Pioglitazone and Rosiglitazone and they are indicated in
the treatment of type 2 diabetes mellitus.
·
TZDs
are insulin sensitizers and are metabolized primarily by the CYP2C8 enzyme.
·
TZDs
bind to peroxisome proliferator-activated receptors gamma (PPARγ) of adipose
tissue, liver, and skeletal muscle cells and induce the glucoregulatory
molecules to enhance the insulin sensitivity.
·
The
drugs inhibiting or inducing CYP2C8 enzyme may result in pharmacokinetic drug
interactions of TZDs.
·
Drugs increasing the
risk of Concentration-dependent adverse effects of TZDs
Ø Gemfibrozil
Ø Clopidogrel
Ø Ketoconazole
Ø Trimethoprim
·
Drugs decreasing
Therapeutic efficacy of TZDs
Ø Rifampicin
·
Healthcare
professionals through the screening, education, and follow up on suspected drug
interactions could reduce the risk of adverse effects.
·
The diabetic patients
should always consult their physician and pharmacist before taking any new
medication.
·
The diabetic patients should bring a list of
all of the drugs they are taking (or simply bring the drugs themselves),
including prescription drugs, over-the-counter drugs, and any supplements,
herbal or otherwise, during their visit to the doctor or pharmacist.
·
They are encouraged to
ask their doctor or pharmacist to look over their list for any potentially
dangerous combinations.
·
It is recommended that people fill all their
prescriptions at one pharmacy, if possible.
